Dexcom is in seventh heaven: A year after its initial FDA submission, the diabetes tech maker has finally gotten the green light to begin rolling out its latest continuous glucose monitor system in ...
LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
It takes two: After making its commercial debut early this year, Dexcom’s latest continuous glucose monitor is wrapping up 2023 by connecting with its first automated insulin pump partner, courtesy of ...
The FDA is aware that Dexcom has sent all affected customers an Urgent Medical Device Correction Notification for the Dexcom G7 Continuous Glucose Monitoring (CGM) App (for Android, iOS, and watchOS ...
Tandem Diabetes Care, Inc.’s TNDM Mobi insulin pump with Control-IQ technology is now fully compatible with both Dexcom’s DXCM G7 and G6 Continuous Glucose Monitoring (“CGM”) Systems. The world’s ...
Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...
The Food and Drug Administration (FDA) has expanded the use of Dexcom's G5 Mobile Continuous Glucose Monitoring (CGM) System to allow for replacement of blood glucose testing for diabetes treatment ...
For quite some time now, there has been significant hype around the Dexcom G7, which received a CE mark in March. This week, as part of a global streaming launch event, Dexcom revealed how the product ...
Dexcom has rebounded since my last update, but I maintain a 'Hold' rating due to continued overvaluation and limited upside potential. Growth remains solid, especially in sensors and U.S. expansion, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback